Stover, Daniel G.

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Kuderer, N. M., Choueiri, T. K., Shah, D. P., Shyr, Y., Rubinstein, S. M., Rivera, D. R., Shete, S., Hsu, C.-Y., Desai, A., de Lima Lopes, G., et al. (2020) · The Lancet

COVID-19 and healthcare impactsCOVID-19 Clinical Research Studies

Cited by 1,726

Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer

Shu, S., Lin, C. Y., He, H. H., Witwicki, R. M., Tabassum, D. P., Roberts, J. M., Janiszewska, M., Jin Huh, S., Liang, Y., Ryan, J., et al. (2016) · Nature

Protein Degradation and InhibitorsChromatin Remodeling and Cancer

Cited by 632

CDK12 inhibition reverses de novo and acquired PARP inhibitor resistance in BRCA Wild-Type and mutated models of Triple-Negative breast Cancer

Johnson, S. F., Cruz, C., Greifenberg, A. K., Dust, S., Stover, D. G., Chi, D., Primack, B., Cao, S., Bernhardy, A. J., Coulson, R., et al. (2016) · Cell Reports

PARP inhibition in cancer therapyAdvanced Breast Cancer Therapies

Cited by 291

Interferon signaling is diminished with age and is associated with immune checkpoint blockade efficacy in triple-negative breast cancer

Sceneay, J., Goreczny, G. J., Wilson, K., Morrow, S., DeCristo, M. J., Ubellacker, J. M., Qin, Y., Laszewski, T., Stover, D. G., Barrera, V., et al. (2019) · Cancer Discovery

Cancer Immunotherapy and Biomarkersinterferon and immune responses

Cited by 156

Unlocking the Potential of ctDNA in Sarcomas: A Review of Recent Advances

Aiyer, S., Kim, T.-H., Collier, K., Pollock, R., Verschraegen, C., Stover, D. G., & Tinoco, G. (2025) · Cancers

Cancer Genomics and DiagnosticsSarcoma Diagnosis and Treatment

Cited by 11